From tumor size and HER2 status to systems oncology for very early breast cancer treatment

Expert Review of Anticancer Therapy

Volumn 10, Issue 2, 2010, Pages 123-128

  Roukos, Dimitrios H ^a   Ziogas, Dimosthenis ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER MORTALITY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER STEM CELL; CANCER THERAPY; CLINICAL DECISION MAKING; DNA SEQUENCE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FOLLOW UP; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HEALTH CARE PRACTICE; HIGH RISK POPULATION; HUMAN; MASTECTOMY; MICROMETASTASIS; MOLECULAR GENETICS; ONCOLOGY; PRACTICE GUIDELINE; PROGNOSIS; RECURRENCE RISK; RETROSPECTIVE STUDY;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; DECISION MAKING; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASTIC STEM CELLS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 76749112093     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.177     Document Type: Editorial

References (44)

1. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 20(8), 1319-1329 (2009).
2. National Comprehensive Cancer Network. Guidelines for Treatment of Cancer by Site. National Comprehensive Cancer Network, PA, USA (2009).
3. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N. Engl. J. Med. 353(16), 1652-1654 (2005).
4. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N. Engl. J. Med. 353(16), 1734-1736 (2005).
5. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 458(7239), 719-724 (2009).
6. Shendure J, Ji H. Next-generation DNA sequencing. Nat. Biotechnol. 26, 1135-1145 (2008).
7. Friedman A, Perrimon N. Genetic screening for signal transduction in the era of network biology. Cell 128, 225-231 (2007).
8. Deisboeck TS. Personalizing medicine: a systems biology perspective. Mol. Syst. Biol. 5, 249 (2009).
9. Roukos DH. Novel clinico-genome network modelling for revolutionizing genotypephenotype-based personalized cancer care. Exp. Rev. Mol. Diagn. 10(1), 33-48 (2010).
10. Gonzalez-Angulo AM, Litton JK, Broglio KR et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J. Clin. Oncol. 27(34), 5700-5706 (2009).
11. Curigliano G, Viale G, Bagnardi V. Clinical relevance of HER2 overexpression/ amplification in patients with small tumor size and node-negative breast cancer. J. Clin. Oncol. 27(34), 5693-5699 (2009).
12. Joensuu H, Isola J, Lundin M et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin. Cancer Res. 9(3), 923-930 (2003).
13. Black D, Younger J, Martei Y et al. Recurrence risk in T1a-b, node-negative, HER2 positive breast cancer. Breast Cancer Res. Treat. 100(Suppl. 1), S92 (2006) (Abstract 2037).
14. Rakkhit R, Broglio K, Peintinger F et al. Significant increased recurrence rates among breast cancer patients with HER2 positive, T1a-b,N0M0 tumors. Cancer Therapy and Reseach Center at University of Texas - American Association for Cancer Research Breast Cancer Symposium, San Antonio, TX, December 10-14, (2008). Cancer Res. 69(Suppl.), S96 (2009) (Abstract 701).
15. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354(8), 809-820 (2006).
16. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005).
17. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005).
18. Slamon D, Eiermann W, Robert N et al. BCIRG 006: 2nd interim analysis Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2/neu positive early breast cancer patients. Presented at: 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14-17 December 2006.
19. Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J. Clin. Oncol. 25(33), 5203-5209 (2007).
20. Roukos DH. Radiation therapy for breast cancer. N. Engl. J. Med. 360(13), 1362 (2009).
21. Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann. Surg. Oncol. 17, 14-17 (2010).
22. Viani G, Afonso S, Stefano E et al. Adjuvant trastuzumab in the treatment of HER-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7, 153 (2007).
23. de Boer M, van Deurzen CH, van Dijck JA et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N. Engl. J. Med. 361(7), 653-663 (2009).
24. Roukos DH. Isolated tumor cells in breast cancer. N. Engl. J. Med. 361, 1994-1995 (2009).
25. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360(8), 790-800 (2009).
26. Roukos DH. Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J. Clin. Oncol. 27(8), 1337-1338 (2009).
27. Fisher B, Dignam J, Tan-Chiu E et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J. Natl Cancer Inst. 93, 112-120 (2001).
28. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365, 1687-1717 (2005).
29. Miller DG. On the nature of susceptibility to cancer. The presidential address. Cancer 46, 1307-1318 (1980).
30. Schinzel AC, Hahn WC. Oncogenic transformation and experimental models of human cancer. Front. Biosci. 13, 71-84 (2008).
31. Wood LD, Parsons DW, Jones S. The genomic landscapes of human breast and colorectal cancers. Science 318(5853), 1108-1113 (2007).
32. Jones S, Zhang X, Parsons DW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897), 1801-1806 (2008).
33. Bastiaens P. Systems biology: when it is time to die. Nature 459(7245), 334-335 (2009).
34. Liu S, Dontu G, Mantle ID et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66, 6063-6071 (2006).
35. Prasad CP, Gupta SD, Rath G et al. Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between b-catenin, disheveled and cyclin D1 expression. Oncology 73, 112-117 (2007).
36. Farnie G, Clarke R. Mammary stem cells and breast cancer - role of notch signaling. Stem Cell Rev. 3, 169-175 (2007).
37. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983-3988 (2003).
38. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004).
39. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-110 (2007).
40. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111-115 (2007).
41. Schatton T, Murphy GF, Frank NY et al. Identification of cells initiating human melanomas. Nature 451, 345-349 (2008).
42. Pommier SJ, Quan GG, Christante D et al. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells. Ann. Surg. Oncol. DOI: 10.1245/s10434-009-0730-z (2009) (Epub ahead of print).
43. Tomasson MH. Cancer stem cells: a guide for skeptics. J. Cell. Biochem. 106(5), 745-749 (2009).
44. Eaves CJ. Cancer stem cells: here, there, everywhere? Nature 456(7222), 581-582 (2008).